- Home
- ATYR vs SOL Comparison
ATYR vs SOL Comparison
Compare ATYR & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- SOL
- Stock Information
- Founded
- ATYR 2005
- SOL 2005
- Country
- ATYR United States
- SOL United States
- Employees
- ATYR N/A
- SOL N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- SOL Semiconductors
- Sector
- ATYR Health Care
- SOL Technology
- Exchange
- ATYR Nasdaq
- SOL Nasdaq
- Market Cap
- ATYR 306.2M
- SOL 94.9M
- IPO Year
- ATYR 2015
- SOL 2008
- Fundamental
- Price
- ATYR $5.31
- SOL $1.92
- Analyst Decision
- ATYR Strong Buy
- SOL Strong Buy
- Analyst Count
- ATYR 6
- SOL 2
- Target Price
- ATYR $20.20
- SOL $4.50
- AVG Volume (30 Days)
- ATYR 3.5M
- SOL 351.5K
- Earning Date
- ATYR 08-12-2025
- SOL 08-19-2025
- Dividend Yield
- ATYR N/A
- SOL N/A
- EPS Growth
- ATYR N/A
- SOL N/A
- EPS
- ATYR N/A
- SOL N/A
- Revenue
- ATYR N/A
- SOL $85,621,000.00
- Revenue This Year
- ATYR $960.85
- SOL N/A
- Revenue Next Year
- ATYR $1,283.47
- SOL $45.37
- P/E Ratio
- ATYR N/A
- SOL N/A
- Revenue Growth
- ATYR N/A
- SOL N/A
- 52 Week Low
- ATYR $1.48
- SOL $1.04
- 52 Week High
- ATYR $5.98
- SOL $3.00
- Technical
- Relative Strength Index (RSI)
- ATYR 57.23
- SOL 62.80
- Support Level
- ATYR $4.96
- SOL $1.84
- Resistance Level
- ATYR $5.47
- SOL $1.91
- Average True Range (ATR)
- ATYR 0.37
- SOL 0.05
- MACD
- ATYR -0.07
- SOL -0.00
- Stochastic Oscillator
- ATYR 61.11
- SOL 95.65
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has globalised Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. Majority of revenue is From Electricity Generation. The company operates in China, USA, Germany, UK, Spain, France, Poland, Italy, Hungary, Luxembourg. Majority of revenue is from Italy.